MedPath

Compareing effects of venlafaxine and Placebo on depression, withdrawal symptoms, craving

Phase 2
Conditions
Addiction.
Mental and behavioral disorders due to use of other stimulants, including caffeine: dependence syndromes
Registration Number
IRCT20160717028967N8
Lead Sponsor
Kermanshah University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Male
Target Recruitment
66
Inclusion Criteria

Gender Male
Methamphetamine dependence diagnoses accordingly Diagnostic and Statistical Manual of Mental Disorders fifth edition
The dominant use of methamphetamine for at least 6 months
lack of serious psychiatric disorders

Exclusion Criteria

Gender female
No use of other drugs and stimulants at the time of entering the study
The absence of comorbid psychiatric disorders symptoms

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Depression. Timepoint: before intervention- 4 weeks later- 8 weeks later. Method of measurement: Depression Inventory.;Withdrawal symptoms. Timepoint: before intervention- 4 weeks later- 8 weeks later. Method of measurement: Inventory withdrawal symptoms.;Craving. Timepoint: before intervention- 4 weeks later- 8 weeks later. Method of measurement: Craving Questionnaire.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath